2021/11/09 -- Singleron Biotechnologies, an innovative biotech company dedicated to applying groundbreaking single cell multi-omics technologies to clinical applications, drug development, and health management, recently completed its oversubscribed Series B financing, raising close to $100M. New investors include Lake Bleu Capital, Firstred Capital and MSA Capital, joined by existing investors Sherpa Healthcare Partners, Lilly Asia Ventures (LAV), ARCH Venture Partners, CDG Capital, CDH Investments, Superstring Capital, 3w Global Investment, and SBCVC.
Founded in 2018, Singleron develops and commercializes single cell multi-omics products that can be used in both research and clinical settings. Its current product portfolio includes instruments, microfluidic systems, reagents, software solutions, and database that facilitate high-throughput single cell multi-omics analysis. The company currently has offices, laboratories, and manufacturing facilities in China, Germany, and the US. Its products are already serving over 1000 laboratories in hospitals, research institutes, and pharmaceutical companies. Singleron will invest the proceeds from this round of financing to further speed up the development of its single-cell platform products, to obtain regulatory approval for in vitro diagnostics products based on its single cell technologies; and to ramp up its international presence